Developing a new treatment for pancreatic cancer using targeted drug delivery
Official title: Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)
Funded at Accuronix Therapeutics, INC. · NIH-10435565 · Data updated 2026-11-12
This study is testing a new oral medication called ACXT-3102 that aims to specifically attack pancreatic cancer cells while being gentle on healthy cells, making treatment easier and more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Accuronix Therapeutics, INC. NIH-funded |
| Lab location | 1 site (St. Louis, UNITED STATES) |
| Project start | September 23, 2019 |
| Project end | July 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $1,019,186 |
| NIH project number | 5R42CA239853-03 |
| Project ID | NIH-10435565 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic adenocarcinoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of cancer or those who do not have pancreatic adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on creating a novel drug, ACXT-3102, specifically designed to target pancreatic cancer cells while minimizing side effects on healthy cells. The approach utilizes a unique mechanism that enhances the drug's effectiveness by binding it to a molecule that induces cancer cell death. By optimizing the drug's formulation for oral administration, the researchers aim to improve patient convenience and treatment outcomes. The study will involve collaboration with experts from Washington University to ensure thorough development and testing of this promising therapy.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less toxic treatment option for patients with pancreatic cancer.
How similar studies have gone: Previous research has shown promise in targeted drug delivery for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Accuronix Therapeutics, INC.
St. Louis, United States Active
Researchers
- Principal investigator: Keller, Bradley T. — Accuronix Therapeutics, INC.
- Study coordinator: Keller, Bradley T.
Related research
Other NIH-funded projects on the same topics.
-
PASSCODE: Coordinating and Sharing PDAC stromal research data
A networked effort at NYU School of Medicine aims to study how the pancreatic cancer stroma shapes tumor growth and patient outcomes, by coordinating researchers, sharing data, and educating the field.
-
Oncostatin M Receptor in Pancreatic Cancer
Aims to understand how a molecule called Oncostatin M and its receptor affect pancreatic cancer to find new ways to help patients.
-
Total Neoadjuvant Therapy for Borderline or Locally Advanced Pancreatic Cancer
A multi-part treatment approach tests giving all chemotherapy and targeted radiotherapy before surgery to help patients with tough-to-remove pancreatic cancer become eligible for curative surgery.
-
Low-dose, motion-aware MRI to study pancreatic cancer
A new MRI method using low-dose contrast and motion-resolved imaging is being explored to better characterize pancreatic cancer in patients.
-
SOAT1 as a target in pancreatic cancer
Researchers are studying a specific enzyme, SOAT1, to see if blocking it can slow down or stop pancreatic cancer progression in models that mimic human disease.
-
Turning inflammatory scar cells in the pancreas into helpers to improve treatment response
This project will try to change inflammatory, scar-forming cells around pancreatic tumors so treatments and the immune system can work better for people with pancreatic ductal adenocarcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.